Not an actual patient.
Are your patients at risk?
Patients with Familial Chylomicronemia Syndrome (FCS) experience persistently elevated triglyceride levels despite standard of care1
FCS is an extreme form of severe hypertriglyceridemia (sHTG) caused by genetic variants that impair lipoprotein lipase (LPL) activity and triglyceride metabolism leading to extremely high triglycerides that are unresponsive to traditional triglyceride-lowering treatments like niacins and fibrates.1
FCS is characterized by very high plasma triglyceride concentrations, a key characteristic of which is milky-looking plasma, caused by a white chylomicron layer floating at the top of the sample1,2
Patients with FCS are at a significant risk for severe complications including acute pancreatitis, which can be fatal1,3,4
Diagnosing your patients with FCS1,4,5,6
If your patients have fasting triglycerides ≥880 mg/dL, it could be a sign that they have FCS, which can be confirmed either genetically or through a clinical diagnosis. Consider a diagnosis using the checklist below.
and ONE of the following:
*In excess of 1000 mg/dL at least 3 times; refractory to lipid-lowering therapy.6
FCS is characterized by a range of clinical symptoms, including acute pancreatitis1
Acute pancreatitis is the most serious and potentially fatal complication of extremely high triglycerides.1,4
Acute pancreatitis caused by high triglycerides is often more severe than acute pancreatitis caused by other factors.7,8
Patients with hypertriglyceridemia, like those with FCS, face a mortality rate from triglyceride-induced acute pancreatitis of up to 6%.9,10
People with triglyceride levels of ≥500 mg/dL are at a high risk for acute pancreatitis11
Expert guidelines support lowering triglycerides below 500 mg/dL to reduce the risk of acute pancreatitis.12,13
Retrospective cohort study annualized incidence rate of acute pancreatitis. Data were obtained from IQVIA's US Ambulatory Electronic Medical Records database (N=7,119,195).11
The American Association of Clinical Endocrinology (AACE) recommends that patients with lipid disorders like FCS should get their lipids checked every 3 months or more frequently as necessary12
Patients with FCS face significant clinical, physical, and psychosocial burdens3,4
FCS is associated with a broad and debilitating symptom profile that affects both physical health and quality of life, including3,4:
Lipemia retinalis
Hepatosplenomegaly
Recurrent episodes of mild to severe abdominal pain
Fatigue and difficulty concentrating
Failure to thrive
Nausea and vomiting
Eruptive xanthomas
Ongoing physical, emotional, and cognitive burdens significantly impact quality of life and mental health.3,4
Are your patients ready for Redemplo®?
Meet some who may be.
Suspected FCS Patient Collapse
Collapse
Rachel
29 years old | Female
Healthy, other than multiple episodes of severe abdominal pain without explainable cause, some leading to hospitalization
Does her best maintaining a strict diet and has lost hope after many medical interventions, including fibrates showing limited efficacy
Extremely high triglyceride levels (>1000 mg/dL) with no history of alcoholism, cholelithiasis, or kidney disease
Not an actual patient.
Current FCS Patient Collapse
Collapse
Not an actual patient.
Reid
47 years old | Male
Extremely high triglyceride levels (consistently >1500-2500 mg/dL) with no history of diabetes or obesity
Recurrent pancreatitis (3 episodes over past 5 years), fatigue, and difficulty concentrating
Has discontinued moderate alcohol use and does his best to maintain a low-fat diet
Family history of high cholesterol and abdominal pain, potentially consistent with pancreatitis
Not an actual patient.
Proven results in patients with FCS6
Convenient dosing: one dose every 3 months6
AP, acute pancreatitis; HTG, hypertriglyceridemia.
REFERENCES Collapse
Collapse
- Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association. J Clin Lipidol. 2025;19(3):382-403.
- Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-272.
- Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15(4):395-405.
- Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2. doi:10.1016/j.jacl.2018.04.009
- Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract. 2018;24(8):756-763.
- Redemplo. Prescribing information. Arrowhead Pharmaceuticals, Inc.; 2025.
- Bálint ER, Für G, Kiss L, et al. Assessment of the course of acute pancreatitis in the light of aetiology: a systemic review and meta-analysis. Sci Rep. 2020;10(1):17936. doi:10.1038/s41598-020-74943-8
- Lu J, Wang Z, Mei W, et al. A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis. BMC Gastroenterol. 2025;25(1):374. doi:10.1186/s12876-025-03954-4
- Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. AM J Gastroenterol. 1995;90912:2134-2139.
- Fan Z, Zhang Y, Li J, et al. Global burden and characterization of hypertriglyceridemia-induced acute pancreatitis: results from a systematic review and a multi-center cohort study. Sci China Life Sci. 2025;68(10):3010-3020. doi:10.1007/s11427-024-2900-6
- Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8
- Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224.
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e1-e123. doi:10.1161/CIR.0000000000001423.
Indication & Important Safety Information
Indication
REDEMPLO® (plozasiran) 25 mg injection is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Important Safety Information
CONTRAINDICATIONS: None.
ADVERSE REACTIONS: Most common adverse reactions occurring in ≥10% of REDEMPLO-treated patients are hyperglycemia, headache, nausea, and injection site reaction.